{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:50:25Z","timestamp":1776873025651,"version":"3.51.2"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020488","name":"Vagelos College of Physicians and Surgeons, Columbia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["218466\/Z\/19\/Z"],"award-info":[{"award-number":["218466\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006346","name":"Hope for Depression Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006474","name":"Columbia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006474","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.neuropharm.2026.110909","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T07:53:12Z","timestamp":1772869992000},"page":"110909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Differential inhibition of the diverse behavioural effects of mu-opioid receptor agonists by progressive receptor depletion"],"prefix":"10.1016","volume":"291","author":[{"given":"Lauren","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cory","family":"Langreck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Hough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mel","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8514-0827","authenticated-orcid":false,"given":"Stephen J.","family":"Briddon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-7875","authenticated-orcid":false,"given":"J. Robert","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Javitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7942-5006","authenticated-orcid":false,"given":"Meritxell","family":"Canals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neuropharm.2026.110909_bib1","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/bph.12445","article-title":"The Concise Guide to PHARMACOLOGY 2013\/14: g protein\u2010coupled receptors","volume":"170","author":"Alexander","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110909_bib2","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62552","article-title":"\u00df-arrestin 2 germline knockout does not attenuate opioid respiratory depression","volume":"10","author":"Bachmutsky","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.neuropharm.2026.110909_bib3","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52694","article-title":"Opioids depress breathing through two small brainstem sites","volume":"9","author":"Bachmutsky","year":"2020","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110909_bib4","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1038\/s41467-021-23736-2","article-title":"Site selective C\u2013H functionalization of Mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy","volume":"12","author":"Bhowmik","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.neuropharm.2026.110909_bib5","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.peptides.2011.09.020","article-title":"Endogenous opiates and behavior: 2010","volume":"32","author":"Bodnar","year":"2011","journal-title":"Peptides"},{"issue":"6813","key":"10.1016\/j.neuropharm.2026.110909_bib6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/35047086","article-title":"Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence","volume":"408","author":"Bohn","year":"2000","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.neuropharm.2026.110909_bib7","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1523\/JNEUROSCI.22-23-10494.2002","article-title":"Differential mechanisms of morphine antinociceptive tolerance revealed in \u03b2arrestin-2 knock-out mice","volume":"22","author":"Bohn","year":"2002","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.110909_bib8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.biopsych.2015.04.022","article-title":"Ketamine as a prophylactic against stress-induced depressive-like behavior","volume":"79","author":"Brachman","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110909_bib9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0022-3565(24)39155-4","article-title":"Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, \u03b2-funaltrexamine, and \u03b2-chlornaltrexamine","volume":"294","author":"Broadbear","year":"2000","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110909_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.pbb.2009.01.019","article-title":"Receptor reserve reflects differential intrinsic efficacy associated with opioid diastereomers","volume":"92","author":"Carliss","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"18","key":"10.1016\/j.neuropharm.2026.110909_bib11","doi-asserted-by":"crossref","first-page":"13873","DOI":"10.1021\/acs.jmedchem.1c01273","article-title":"A novel mitragynine analog with low-efficacy Mu opioid receptor agonism displays antinociception with attenuated adverse effects","volume":"64","author":"Chakraborty","year":"2021","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.110909_bib12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41386-020-0714-z","article-title":"Sex-specific neurobiological actions of prophylactic (R, S)-ketamine,(2 R, 6 R)-hydroxynorketamine, and (2 S, 6 S)-hydroxynorketamine","volume":"45","author":"Chen","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.neuropharm.2026.110909_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.biopsych.2021.04.024","article-title":"Fluoroethylnormemantine, a novel NMDA receptor antagonist, for the prevention and treatment of stress-induced maladaptive behavior","volume":"90","author":"Chen","year":"2021","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110909_bib14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41386-019-0540-3","article-title":"Prophylactic efficacy of 5-HT4R agonists against stress","volume":"45","author":"Chen","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.neuropharm.2026.110909_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0165-6147(97)01138-3","article-title":"The elusive nature of intrinsic efficacy","volume":"19","author":"Clarke","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110909_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF03190130","article-title":"Kinetic profiles of tianeptine and its MC5 metabolite in plasma, blood and brain after single and chronic intraperitoneal administration in the rat","volume":"15","author":"Couet","year":"1990","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.neuropharm.2026.110909_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1037\/a0012931","article-title":"Sex differences in analgesic, reinforcing, discriminative, and motoric effects of opioids","volume":"16","author":"Craft","year":"2008","journal-title":"Exp. Clin. Psychopharmacol"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110909_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tins.2011.11.005","article-title":"The neurobiology of anhedonia and other reward-related deficits","volume":"35","author":"Der-Avakian","year":"2012","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110909_bib18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/jpet.119.262717","article-title":"Pharmacological properties of \u03b4-Opioid receptor-mediated behaviors: agonist efficacy and receptor Reserve","volume":"374","author":"Dripps","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110909_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G\u2217Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110909_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1345\/aph.10121","article-title":"Opioid antagonists in the treatment of opioid-induced constipation and pruritus","volume":"35","author":"Friedman","year":"2001","journal-title":"Ann. Pharmacother."},{"issue":"7","key":"10.1016\/j.neuropharm.2026.110909_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.30","article-title":"The atypical antidepressant and neurorestorative agent tianeptine is a \u03bc-opioid receptor agonist","volume":"4","author":"Gassaway","year":"2014","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110909_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1124\/jpet.119.260331","article-title":"Methocinnamox produces long-lasting antagonism of the behavioral effects of \u03bc-opioid receptor agonists but not prolonged precipitated withdrawal in rats","volume":"371","author":"Gerak","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"625","key":"10.1016\/j.neuropharm.2026.110909_bib23","doi-asserted-by":"crossref","first-page":"eaaz3140","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci. Signal."},{"issue":"12","key":"10.1016\/j.neuropharm.2026.110909_bib24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.tips.2020.09.009","article-title":"Critical assessment of G protein-biased agonism at the \u03bc-opioid receptor","volume":"41","author":"Gillis","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"13","key":"10.1016\/j.neuropharm.2026.110909_bib25","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41386-021-01054-x","article-title":"Pharmacological and genetic manipulations at the \u03bc-opioid receptor reveal arrestin-3 engagement limits analgesic tolerance and does not exacerbate respiratory depression in mice","volume":"46","author":"He","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110909_bib26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bph.12633","article-title":"The \u03bc\u2010opioid receptor: an electrophysiologist's perspective from the sharp end","volume":"172","author":"Henderson","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.110909_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107961","article-title":"Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology","volume":"230","author":"Hill","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"14","key":"10.1016\/j.neuropharm.2026.110909_bib28","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1111\/bph.15832","article-title":"The respiratory depressant effects of mitragynine are limited by its conversion to 7\u2010OH mitragynine","volume":"179","author":"Hill","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2026.110909_bib29","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bph.12222","article-title":"Efficacy and ligand bias at the \u03bc-opioid receptor","volume":"169","author":"Kelly","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"13","key":"10.1016\/j.neuropharm.2026.110909_bib30","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/bph.15004","article-title":"Morphine\u2010induced respiratory depression is independent of \u03b2\u2010arrestin2 signalling","volume":"177","author":"Kliewer","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110909_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u03bc-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.110909_bib32","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1021\/acscentsci.9b00141","article-title":"7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects","volume":"5","author":"Kruegel","year":"2019","journal-title":"ACS Cent. Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110909_bib33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends Neurosci."},{"issue":"539","key":"10.1016\/j.neuropharm.2026.110909_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aas9609","article-title":"Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid \u03bc-opioid receptor desensitization","volume":"11","author":"Miess","year":"2018","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110909_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s002130050734","article-title":"The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor","volume":"140","author":"Morgan","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"10.1016\/j.neuropharm.2026.110909_bib36","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1177\/0271678X20943823","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"40","author":"Percie du Sert","year":"2020","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110909_bib37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/jm00177a002","article-title":"A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities","volume":"23","author":"Portoghese","year":"1980","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110909_bib38","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0022-3565(25)20154-9","article-title":"Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice","volume":"252","author":"Qi","year":"1990","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110909_bib39","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in \u03b2-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.110909_bib40","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/npp.2017.60","article-title":"The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor","volume":"42","author":"Samuels","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110909_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/jpet.121.001045","article-title":"Role of efficacy as a determinant of locomotor activation by Mu opioid receptor ligands in female and Male mice","volume":"382","author":"Santos","year":"2022","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110909_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0023677217724823","article-title":"PREPARE: guidelines for planning animal research and testing","volume":"52","author":"Smith","year":"2018","journal-title":"Lab. Anim"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110909_bib43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0893-133X(00)00252-9","article-title":"\u03bc Opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo \u03bc receptor reserve","volume":"25","author":"Sora","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2026.110909_bib44","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/JPR.S171013","article-title":"APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u03bc-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy","author":"Viscusi","year":"2019","journal-title":"J. Pain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110909_bib45","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110909_bib46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/wps.20633","article-title":"Addressing the opioid crisis globally","volume":"18","author":"Volkow","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neuropharm.2026.110909_bib47","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.2147\/DDDT.S475205","article-title":"Global trends in oliceridine (TRV130) research from 2013 to 2024: a bibliometrics and knowledge graph analysis","author":"Wang","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110909_bib48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/pr.112.005942","article-title":"Regulation of \u03bc-opioid receptors: desensitization, phosphorylation, internalization, and tolerance","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"10.1016\/j.neuropharm.2026.110909_bib49","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1073\/pnas.95.12.7157","article-title":"Role for G protein-coupled receptor kinase in agonist-specific regulation of \u03bc-opioid receptor responsiveness","volume":"95","author":"Zhang","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.neuropharm.2026.110909_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103720","article-title":"Mitragynine and 7-hydroxymitragynine: bidirectional effects on breathing in rats","volume":"392","author":"Zuarth Gonzalez","year":"2025","journal-title":"J. Pharmacol. Exp. Therapeut."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826000821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826000821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:10:32Z","timestamp":1776096632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826000821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"alternative-id":["S0028390826000821"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.110909","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential inhibition of the diverse behavioural effects of mu-opioid receptor agonists by progressive receptor depletion","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.110909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110909"}}